ALSO NOTED: Guidant warns on defibrillators; FDA approves new Adderall use;and much more...

> Guidant said one of the recommendations it made to physicians in June designed to correct a problem with its recently recalled implantable defibrillators may actually increase risk to patients. Story

> Shire Pharmaceuticals received FDA approval to market Adderall to treat adolescents. Release

> Alpharma is expanding its warning on Kadian. Release

> Myogen has completed enrollment in its Phase III trial of ambrisentan. Release

And Finally... A new study shows a single dose of the anticancer drug carboplatin is as successful and less toxic than previous testicular cancer  treatments, and it is comparable to radiation in effectiveness. Story

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.